Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
17 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03549273 | Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions | unknown | Phase 2 | 62 | Catalysis SLINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03549494 | Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction | completed | Phase 2 | 45 | Catalysis SLINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03559543 |
| Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma |
| completed |
| Phase 2 |
| 40 |
| Catalysis SLINDUSTRY |
| 1 |
| Feb 7, 2024 |
| clinicaltrials |
| NCT03674112 | A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer(PHranceSCa) | completed | Phase 2 | 160 | Hoffmann-La RocheINDUSTRY | 17 | Jan 2, 2024 | clinicaltrials |
| NCT03717298 | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 30 | Catalysis SLINDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03562897 | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | completed | Phase 2 | 40 | Catalysis SLINDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT03540407 | Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma. | completed | Phase 2 | 66 | Catalysis SLINDUSTRY | 1 | Jan 23, 2020 | clinicaltrials |
| NCT03543670 | Evaluation of Oncoxin-Viusid® in Prostate Cancer | completed | Phase 2 | 25 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT03584308 | Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal | completed | Phase 2 | 110 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT03576521 | Evaluation of Ocoxin®-Viusid® in Breast Cancer | completed | Phase 2 | 120 | Catalysis SLINDUSTRY | 1 | Jul 3, 2018 | clinicaltrials |
| NCT03541772 | Evaluation of Oncoxin-Viusid® in Head and Neck Cancer | completed | Phase 2 | 60 | Catalysis SLINDUSTRY | 1 | Jun 6, 2018 | clinicaltrials |
| NCT03541148 | Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma | completed | Phase 2 | 20 | Catalysis SLINDUSTRY | 1 | May 30, 2018 | clinicaltrials |
| NCT01145170 | Nimotuzumab and Radiotherapy in Pediatric Patients With Glioma(POLARIS) | completed | Phase 2 | 40 | Eurofarma Laboratorios S.A.INDUSTRY | 2 | Jul 27, 2015 | clinicaltrials |
| NCT00886873 | Mifepristone 10 or 5 mg for 6 Months to Treat Uterine Fibroids(Mifemyo_2) | completed | Phase 2 / Phase 3 | 100 | Mediterranea Medica S. L.OTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT01786226 | Mifepristone to Treat Uterine Fibroids | terminated | Phase 2 / Phase 3 | 220 | Mediterranea Medica S. L.OTHER | 1 | Sep 5, 2014 | clinicaltrials |
| NCT00872482 | A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases | terminated | Phase 2 | 21 | YM BioSciencesINDUSTRY | 5 | Jul 1, 2011 | clinicaltrials |
| NCT00712595 | Mifepristone for Treatment of Uterine Fibroids(Mifemyo) | completed | Phase 2 / Phase 3 | 200 | Mediterranea Medica S. L.OTHER | 1 | Apr 23, 2009 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials